Stage IB Pancreatic Cancer
13
0
0
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
23.1%
3 terminated out of 13 trials
72.7%
-13.8% vs benchmark
0%
0 trials in Phase 3/4
63%
5 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer
Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Perioperative Therapy for Resectable Pancreatic Cancer
Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer